Status:
UNKNOWN
LMBA02 Protocol for Patients With a Burkitt Lymphoma
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Burkitt Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the ...
Eligibility Criteria
Inclusion
- Age : 18 years or older
- Histologically or cytologically proven Burkitt lymphoma according to the WHO classification
- WHO performance \< 3
- Informed consent
Exclusion
- Known HIV positive infection
- Positive serology for HCV and HBV (except after vaccination)
- Patients previously treated for lymphoma
- cardiac disease that contradict anthracycline chemotherapy
- Psychological or psychiatric condition who contradict steroids therapy
- Patients with serious renal failure unrelated to the lymphoma (serum creatinin level higher than 150 mmole/L)
- Cirrhosis or severe hepatic failure unrelated to the lymphoma
- Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix carcinoma
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Primary organ transplant or other immunosuppressive conditions Pregnancy
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT00180882
Start Date
October 1 2004
Last Update
September 11 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave Roussy
Villejuif, France, 94800